These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6461763)

  • 21. Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses.
    Furr BJ; Woodburn JR
    J Endocrinol Invest; 1988; 11(7):535-57. PubMed ID: 2902123
    [No Abstract]   [Full Text] [Related]  

  • 22. Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma.
    Eisenberger MA; O'Dwyer PJ; Friedman MA
    J Clin Oncol; 1986 Mar; 4(3):414-24. PubMed ID: 2936872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The mechanisms of antitumor effects of luteinizing hormone-releasing hormone agonist (buserelin) in 7, 12-dimethylbenz(a)anthracene-induced rat mammary cancer.
    Koibuchi Y; Sugamata N; Iino Y; Yokoe T; Andoh T; Maemura M; Takei H; Horiguchi J; Matsumoto H; Morishita Y
    Int J Mol Med; 1999 Aug; 4(2):145-8. PubMed ID: 10402480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75.
    Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
    J Natl Cancer Inst; 1990 Mar; 82(6):513-7. PubMed ID: 2156080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrine and cytostatic treatment of experimental mammary cancer.
    Fiebig HH; Schmähl D
    Recent Results Cancer Res; 1980; 71():80-95. PubMed ID: 6768114
    [No Abstract]   [Full Text] [Related]  

  • 26. Combined endocrine therapy and chemotherapy of mouse mammary tumors.
    Sluyser M; de Goeij CC; Evers SG
    Eur J Cancer (1965); 1981 Feb; 17(2):155-9. PubMed ID: 7262152
    [No Abstract]   [Full Text] [Related]  

  • 27. [Synergistic therapeutic effect of adriamycin with 5-fluor-uracil, with prednisolon and with cyclophosphamide on chemically induced mammary cancer of the rat (author's transl)].
    Fiebig HH; Schmähl D
    Klin Wochenschr; 1977 May; 55(9):445-50. PubMed ID: 406478
    [No Abstract]   [Full Text] [Related]  

  • 28. Active immunization to luteinizing hormone releasing hormone to inhibit the induction of mammary tumors in the rat.
    Ravdin PM; Jordan VC
    Life Sci; 1988; 43(2):117-23. PubMed ID: 3134587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of ovariectomy, tamoxifen and the combination adriamycin and 5-FU on 7,12-dimethylbenz(a)anthracene induced mammary cancer of the rat.
    Fiebig HH; Schmähl D
    Oncology; 1977; 34(2):58-61. PubMed ID: 408773
    [No Abstract]   [Full Text] [Related]  

  • 30. LHRH analogues in the treatment of cancer.
    Jackson IM; Matthews MJ; Diver JM
    Cancer Treat Rev; 1989 Sep; 16(3):161-75. PubMed ID: 2695240
    [No Abstract]   [Full Text] [Related]  

  • 31. Hormone therapy of prostatic bone metastases.
    Huben RP
    Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F; Dupont A; Belanger A
    Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of catechol estrogens on rat mammary tumors.
    Abul-Hajj YJ
    Cancer Res; 1979 Dec; 39(12):4882-6. PubMed ID: 115583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Control of experimental breast cancer by antioestrogenic therapies [proceedings].
    Dix CJ; Jordan VC
    Br J Pharmacol; 1979 May; 66(1):66P. PubMed ID: 110387
    [No Abstract]   [Full Text] [Related]  

  • 35. 2-bromo-alpha-ergocryptine (CB-154) and tamoxifen (ICI 46,474) induced suppression of the genesis of mammary carcinomas in female rats treated with 7,12-dimethylbenzanthracene (DMBA): a comparison.
    Welsch CW; Goodrich-Smith M; Brown CK; Mackie D; Johnson D
    Oncology; 1982; 39(2):88-92. PubMed ID: 6801566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neovir, an interferon inductor, modifies expression of steroid hormone receptors in hormone-dependent tissues and restores sensitivity to tamoxifen in patients with inoperable breast cancer].
    Surkov KG; Tsyrlina EV; Konstantinova MM; Bersteĭn LM
    Vopr Onkol; 1996; 42(6):28-32. PubMed ID: 9123898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The interaction of dietary fat and antiestrogen treatment on DMBA-induced mammary tumors in the rat.
    King MM; Pento JT; Magarian RA; Brueggemann G
    Nutr Cancer; 1985; 7(4):239-49. PubMed ID: 3938837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse effect of tamoxifen with LHRH agonist on oestrogen-receptor-negative mammary carcinoma.
    Szende B; Schally AV; Srkalovic G; Comaru-Schally AM; Wittliff JL
    Lancet; 1989 Jul; 2(8656):222-3. PubMed ID: 2568553
    [No Abstract]   [Full Text] [Related]  

  • 39. [Effects of chemo-endocrine therapy on DMBA-induced rat mammary carcinoma].
    Yamamoto H; Morimoto T; Monden A
    Nihon Geka Gakkai Zasshi; 1989 Oct; 90(10):1786-92. PubMed ID: 2512479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian ablation as adjuvant therapy for early-stage breast cancer.
    Pritchard KI
    Cancer Treat Res; 1998; 94():158-80. PubMed ID: 9587687
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.